Skip to main content

Table 3 Changes in BMF grade from baseline for individual patients, according to disease subtype and treatment cycle

From: Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis

Disease subtype BMF grade Change in BMF grade from baseline to last time point evaluated
Baseline (n = 21) Cycle 6 (n = 18) Cycle 12 (n = 16) Cycle 18 (n = 14) Cycle 24 (n = 9) Cycle 30 (n = 9)
PMF 3 2 n/a n/a n/a n/a Improved
PMF 3 2 1 1 n/a 1 Improved
PMF 3 3 n/a 3 n/a n/a Persistent grade 3
PMF 3 3 n/a n/a n/a n/a Persistent grade 3
PMF 3 2 3 n/a 2 2 Improved
PMF 3 2 2 2 2 n/a Improved
PMF 2 3 3 n/a n/a n/a Worsened
PMF 2 2 2 2 n/a n/a Stabilised
PMF 2 n/a 3 n/a n/a n/a Worsened
PMF 2 n/a 3 n/a n/a n/a Worsened
PMF 1 1 2 1 1 1 Stabilised
PMF 1 n/a 0 0 0 n/a Improved
Post-PV MF 3 2 2 3 n/a n/a Persistent grade 3
Post-PV MF 3 3 n/a 3 3 3 Persistent grade 3
Post-PV MF 3 2 3 3 3 n/a Persistent grade 3
Post-PV MF 2 3 2 2 n/a 2 Stabilised
Post-PV MF 2 1 0 0 n/a 0 Improved
Post-PV MF 2 3 3 3 2 3 Worsened
Post-PV MF 2 2 3 n/a 2 2 Stabilised
Post-PV MF 2 2 2 2 1 1 Improved
Post-ET MF 2 1 n/a 3 n/a n/a Worsened
  1. n/a not applicable